Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 1991;83:438-447

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Blankenhorn, D. H.
Right arrow Articles by Wickham, E. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Blankenhorn, D. H.
Right arrow Articles by Wickham, E. C.

Circulation, Vol 83, 438-447, Copyright © 1991 by American Heart Association


ARTICLES

Effects of colestipol-niacin therapy on human femoral atherosclerosis

DH Blankenhorn, SP Azen, DW Crawford, SA Nessim, ME Sanmarco, RH Selzer, AM Shircore and EC Wickham
Department of Medicine, University of Southern California, Los Angeles 90033.

The 2-year therapy effect on femoral atherosclerosis was evaluated in the Cholesterol Lowering Atherosclerosis Study (CLAS), a randomized, placebo-plus-diet-controlled angiographic trial of colestipol-niacin therapy plus diet in men with previous coronary bypass surgery. Different diet compositions were prescribed to enhance the differential in blood cholesterol responses between the two groups. The annual rate of change in computer-estimated atherosclerosis (CEA), a measure of lumen abnormality, was evaluated between treatment groups. A significant per-segment therapy effect was found in segments with moderately severe atherosclerosis (p less than 0.04) and in proximal segments (p less than 0.02). When segmental CEA measures were combined into a per-patient score using an adaptation of the National Heart, Lung, and Blood Institute scoring procedure, a significant therapy effect was observed (p less than 0.02). Total variance of the annual change rate in CEA was as predicted from pilot studies, but measurement variation was larger. The therapy effect observed in femoral arteries, although significant, was less marked than the strong and consistent benefit previously reported for both native coronary arteries and aortocoronary bypass grafts.


This article has been cited by other articles:


Home page
ANGIOLOGYHome page
J. Illnait, G. Castano, E. Alvarez, L. Fernandez, R. Mas, S. Mendoza, and R. Gamez
Effects of Policosanol (10 mg/d) Versus Aspirin (100 mg/d) in Patients With Intermittent Claudication: A 10-Week, Randomized, Comparative Study
Angiology, July 1, 2008; 59(3): 269 - 277.
[Abstract] [PDF]


Home page
JAMAHome page
I. M. Singh, M. H. Shishehbor, and B. J. Ansell
High-Density Lipoprotein as a Therapeutic Target: A Systematic Review
JAMA, August 15, 2007; 298(7): 786 - 798.
[Abstract] [Full Text] [PDF]


Home page
ANGIOLOGYHome page
P. Poredos and B. Jug
The Prevalence of Peripheral Arterial Disease in High Risk Subjects and Coronary or Cerebrovascular Patients
Angiology, July 1, 2007; 58(3): 309 - 315.
[Abstract] [PDF]


Home page
Mayo Clin Proc.Home page
D. G. Federman, D. C. Ranani, R. S. Kirsner, and D. M. Bravata
Lipid-Lowering Therapy in Patients With Peripheral Arterial Disease: Are Guidelines Being Met?
Mayo Clin. Proc., April 1, 2005; 80(4): 494 - 498.
[Abstract] [PDF]


Home page
Mayo Clin Proc.Home page
T. C. Collins, N. J. Petersen, M. Suarez-Almazor, and C. M. Ashton
Ethnicity and Peripheral Arterial Disease
Mayo Clin. Proc., January 1, 2005; 80(1): 48 - 54.
[Abstract] [PDF]


Home page
Eur Heart J SupplHome page
H. Sillesen
What does the future hold for the patient with peripheral arterial disease?
Eur. Heart J. Suppl., July 1, 2004; 6(suppl_C): C43 - C48.
[Abstract] [Full Text] [PDF]


Home page
ANGIOLOGYHome page
K. Kroger
Dyslipoproteinemia and Peripheral Arterial Occlusive Disease
Angiology, March 1, 2004; 55(2): 135 - 138.
[Abstract] [PDF]


Home page
CirculationHome page
E. R. Mohler III, W. R. Hiatt, M. A. Creager, and for the Study Investigators
Cholesterol Reduction With Atorvastatin Improves Walking Distance in Patients With Peripheral Arterial Disease
Circulation, September 23, 2003; 108(12): 1481 - 1486.
[Abstract] [Full Text] [PDF]


Home page
Vasc MedHome page
C. F. Kugler and G. Rudofsky
The challenges of treating peripheral arterial disease
Vascular Medicine, May 1, 2003; 8(2): 109 - 114.
[Abstract] [PDF]


Home page
Vasc MedHome page
A. T Hirsch and A. M Gotto Jr
Undertreatment of dyslipidemia in peripheral arterial disease and other high-risk populations: an opportunity for cardiovascular disease reduction
Vascular Medicine, November 1, 2002; 7(4): 323 - 331.
[Abstract] [PDF]


Home page
J Am Coll CardiolHome page
Y. Sawayama, C. Shimizu, N. Maeda, M. Tatsukawa, N. Kinukawa, S. Koyanagi, S. Kashiwagi, and J. Hayashi
Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia: Fukuoka atherosclerosis trial (FAST)
J. Am. Coll. Cardiol., February 20, 2002; 39(4): 610 - 616.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. R. Kapadia, S. E. Nissen, K. M. Ziada, G. Rincon, T. D. Crowe, N. Boparai, J. B. Young, and E. M. Tuzcu
Impact of lipid abnormalities in development and progression of transplant coronary disease: a serial intravascular ultrasound study
J. Am. Coll. Cardiol., July 1, 2001; 38(1): 206 - 213.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
W. R. Hiatt
Medical Treatment of Peripheral Arterial Disease and Claudication
N. Engl. J. Med., May 24, 2001; 344(21): 1608 - 1621.
[Full Text] [PDF]


Home page
ANGIOLOGYHome page
L. Bokemark, J. Wikstrand, and B. Fagerberg
Intact Insulin, Insulin Propeptides, and Intima-media Thickness in the Femoral Artery in 58-year-old Clinically Healthy Men: The Atherosclerosis and Insulin Resistance Study
Angiology, April 1, 2001; 52(4): 237 - 245.
[Abstract] [PDF]


Home page
Vasc MedHome page
M. H Criqui
Peripheral arterial disease - epidemiological aspects
Vascular Medicine, February 1, 2001; 6(1_suppl): 3 - 7.
[Abstract] [PDF]


Home page
JAMAHome page
D. Steinberg and A. M. Gotto Jr
Preventing Coronary Artery Disease by Lowering Cholesterol Levels: Fifty Years From Bench to Bedside
JAMA, December 1, 1999; 282(21): 2043 - 2050.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M.-L. M. Gronholdt
Ultrasound and Lipoproteins as Predictors of Lipid-Rich, Rupture-Prone Plaques in the Carotid Artery
Arterioscler Thromb Vasc Biol, January 1, 1999; 19(1): 2 - 13.
[Abstract] [Full Text] [PDF]


Home page
ANGIOLOGYHome page
F. J. Vagnini, S. Hill, J. Puvogel, and J. Puvogel
The Use of Multisite High Resolution Arterial Imaging to Assess Arteriosclerosis
Angiology, December 1, 1997; 48(12): 1023 - 1030.
[Abstract] [PDF]


Home page
StrokeHome page
M.-L. M. Gronholdt, B. G. Nordestgaard, T. G. Nielsen, and H. Sillesen
Echolucent Carotid Artery Plaques Are Associated With Elevated Levels of Fasting and Postprandial Triglyceride-Rich Lipoproteins
Stroke, December 1, 1996; 27(12): 2166 - 2172.
[Abstract] [Full Text]


Home page
CirculationHome page
S. P. Azen, D. Qian, W. J. Mack, A. Sevanian, R. H. Selzer, C.-R. Liu, C.-H. Liu, and H. N. Hodis
Effect of Supplementary Antioxidant Vitamin Intake on Carotid Arterial Wall Intima-Media Thickness in a Controlled Clinical Trial of Cholesterol Lowering
Circulation, November 15, 1996; 94(10): 2369 - 2372.
[Abstract] [Full Text]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
J. Johansson, A. G. Olsson, L. Bergstrand, L. S. Elinder, S. Nilsson, U. Erikson, J. Molgaard, I. Holme, and G. Walldius
Lowering of HDL2b by Probucol Partly Explains the Failure of the Drug to Affect Femoral Atherosclerosis in Subjects With Hypercholesterolemia : A Probucol Quantitative Regression Swedish Trial (PQRST) Report
Arterioscler Thromb Vasc Biol, August 1, 1995; 15(8): 1049 - 1056.
[Abstract] [Full Text]


Home page
CirculationHome page
A. M. Gotto Jr
Lipid Lowering, Regression, and Coronary Events : A Review of the Interdisciplinary Council on Lipids and Cardiovascular Risk Intervention, Seventh Council Meeting
Circulation, August 1, 1995; 92(3): 646 - 656.
[Full Text]